Circ: Cardiovascular Interventions:目前的胸外科医师协会模型将TAVR患者的死亡风险重新分类

2018-09-21 xiangting MedSci原创

目前的STS计算方法产生的死亡风险显著低于2008计算法,在有某些特定合并症的患者中更为明显。

胸外科医师协会(STS)评分被用于筛查接受经导管主动脉瓣置换术(TAVR)的患者。STS评分也用于各大TAVR试验中患者的风险分层。这项研究评估了与2008 STS风险模型相比,线上STS评分计算器对TAVR患者的预测死亡风险再分类。

本研究纳入2006年至2016年接受TAVR的所有患者。通过应用2008 STS风险模型计算所有纳入患者的STS评分,并使用当前的STS线上计算器再次进行计算。在1209名接受TAVR的患者中,30天死亡率为27(2.2%)。使用当前的线上STS风险计算器估算的总体预测死亡风险显著低于2008 STS风险模型(6.3±4.4 vs 7.3±4.9;P <0.001)。根据当前的STS风险模型,共有235名(19%)患者被重新归类为风险较低的类别。在多因素logistic 回归分析中,根据当前的STS风险模型,持续性房颤(比值比,1.4;95%CI,1.0-1.9;P=0.03)、慢性心力衰竭(比值比,6.0; 95%CI,3.8-10.1; P<0.001)、纽约心脏病协会IV级心衰(比值比,2.4; 95%CI,1.3-4.4; P = 0.007)更可能被重新归类为较低的风险类别。

目前的STS计算方法产生的死亡风险显著低于2008计算法,在有某些特定合并症的患者中更为明显。在评估既往TAVR研究的数据时应考虑到这些结果。

原始出处:

本文系梅斯医学(MedSci)原创译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086340, encodeId=c5012086340c2, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jul 11 20:40:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938879, encodeId=159c19388e978, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 22 17:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763248, encodeId=91831e6324870, content=<a href='/topic/show?id=f20f18290b8' target=_blank style='color:#2F92EE;'>#vascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18290, encryptionId=f20f18290b8, topicName=vascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03b737453747, createdName=ms1065684921169360, createdTime=Mon Apr 29 19:40:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255800, encodeId=665b125580066, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500944, encodeId=c21e1500944ef, content=<a href='/topic/show?id=a89e410286' target=_blank style='color:#2F92EE;'>#cardiovascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4102, encryptionId=a89e410286, topicName=cardiovascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9c69479578, createdName=珙桐, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346052, encodeId=955b34605241, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 22:00:18 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047613, encodeId=509f104e613ee, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Sep 21 18:40:00 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086340, encodeId=c5012086340c2, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jul 11 20:40:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938879, encodeId=159c19388e978, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 22 17:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763248, encodeId=91831e6324870, content=<a href='/topic/show?id=f20f18290b8' target=_blank style='color:#2F92EE;'>#vascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18290, encryptionId=f20f18290b8, topicName=vascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03b737453747, createdName=ms1065684921169360, createdTime=Mon Apr 29 19:40:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255800, encodeId=665b125580066, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500944, encodeId=c21e1500944ef, content=<a href='/topic/show?id=a89e410286' target=_blank style='color:#2F92EE;'>#cardiovascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4102, encryptionId=a89e410286, topicName=cardiovascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9c69479578, createdName=珙桐, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346052, encodeId=955b34605241, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 22:00:18 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047613, encodeId=509f104e613ee, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Sep 21 18:40:00 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
    2019-05-22 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086340, encodeId=c5012086340c2, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jul 11 20:40:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938879, encodeId=159c19388e978, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 22 17:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763248, encodeId=91831e6324870, content=<a href='/topic/show?id=f20f18290b8' target=_blank style='color:#2F92EE;'>#vascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18290, encryptionId=f20f18290b8, topicName=vascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03b737453747, createdName=ms1065684921169360, createdTime=Mon Apr 29 19:40:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255800, encodeId=665b125580066, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500944, encodeId=c21e1500944ef, content=<a href='/topic/show?id=a89e410286' target=_blank style='color:#2F92EE;'>#cardiovascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4102, encryptionId=a89e410286, topicName=cardiovascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9c69479578, createdName=珙桐, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346052, encodeId=955b34605241, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 22:00:18 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047613, encodeId=509f104e613ee, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Sep 21 18:40:00 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086340, encodeId=c5012086340c2, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jul 11 20:40:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938879, encodeId=159c19388e978, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 22 17:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763248, encodeId=91831e6324870, content=<a href='/topic/show?id=f20f18290b8' target=_blank style='color:#2F92EE;'>#vascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18290, encryptionId=f20f18290b8, topicName=vascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03b737453747, createdName=ms1065684921169360, createdTime=Mon Apr 29 19:40:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255800, encodeId=665b125580066, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500944, encodeId=c21e1500944ef, content=<a href='/topic/show?id=a89e410286' target=_blank style='color:#2F92EE;'>#cardiovascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4102, encryptionId=a89e410286, topicName=cardiovascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9c69479578, createdName=珙桐, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346052, encodeId=955b34605241, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 22:00:18 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047613, encodeId=509f104e613ee, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Sep 21 18:40:00 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086340, encodeId=c5012086340c2, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jul 11 20:40:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938879, encodeId=159c19388e978, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 22 17:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763248, encodeId=91831e6324870, content=<a href='/topic/show?id=f20f18290b8' target=_blank style='color:#2F92EE;'>#vascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18290, encryptionId=f20f18290b8, topicName=vascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03b737453747, createdName=ms1065684921169360, createdTime=Mon Apr 29 19:40:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255800, encodeId=665b125580066, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500944, encodeId=c21e1500944ef, content=<a href='/topic/show?id=a89e410286' target=_blank style='color:#2F92EE;'>#cardiovascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4102, encryptionId=a89e410286, topicName=cardiovascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9c69479578, createdName=珙桐, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346052, encodeId=955b34605241, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 22:00:18 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047613, encodeId=509f104e613ee, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Sep 21 18:40:00 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2086340, encodeId=c5012086340c2, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jul 11 20:40:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938879, encodeId=159c19388e978, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 22 17:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763248, encodeId=91831e6324870, content=<a href='/topic/show?id=f20f18290b8' target=_blank style='color:#2F92EE;'>#vascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18290, encryptionId=f20f18290b8, topicName=vascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03b737453747, createdName=ms1065684921169360, createdTime=Mon Apr 29 19:40:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255800, encodeId=665b125580066, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500944, encodeId=c21e1500944ef, content=<a href='/topic/show?id=a89e410286' target=_blank style='color:#2F92EE;'>#cardiovascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4102, encryptionId=a89e410286, topicName=cardiovascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9c69479578, createdName=珙桐, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346052, encodeId=955b34605241, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 22:00:18 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047613, encodeId=509f104e613ee, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Sep 21 18:40:00 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
    2018-09-21 医者仁心5538

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2086340, encodeId=c5012086340c2, content=<a href='/topic/show?id=134b304456' target=_blank style='color:#2F92EE;'>#AVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3044, encryptionId=134b304456, topicName=AVR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Thu Jul 11 20:40:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938879, encodeId=159c19388e978, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 22 17:40:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1763248, encodeId=91831e6324870, content=<a href='/topic/show?id=f20f18290b8' target=_blank style='color:#2F92EE;'>#vascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18290, encryptionId=f20f18290b8, topicName=vascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03b737453747, createdName=ms1065684921169360, createdTime=Mon Apr 29 19:40:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255800, encodeId=665b125580066, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500944, encodeId=c21e1500944ef, content=<a href='/topic/show?id=a89e410286' target=_blank style='color:#2F92EE;'>#cardiovascular#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4102, encryptionId=a89e410286, topicName=cardiovascular)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f9c69479578, createdName=珙桐, createdTime=Sun Sep 23 06:40:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346052, encodeId=955b34605241, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Fri Sep 21 22:00:18 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047613, encodeId=509f104e613ee, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Sep 21 18:40:00 CST 2018, time=2018-09-21, status=1, ipAttribution=)]
    2018-09-21 CHANGE

    梅斯里提供了很多疾病的模型计算公式,赞一个!

    0

相关资讯

JACC:TAVR后需要晚期(≥48h)永久起搏器的高度传导障碍预测因子

该分析显示在这个队列中,基线右束支传导阻滞和TAVR后PR长度增加数量是TAVR后需要进行PPM置换的晚期(≥48h)高度传导障碍独立预测因子。

JACC:TAVR后新发持续左束支传导阻滞患者的心律失常负担

这些数据支持,在这一具有挑战性的患者群体中使用心脏监测设备进行密切随访,并尽早治疗。

JACC:经导管主动脉瓣置换术后新发房颤的发病率、治疗和相关临床结局

TAVR术后AF的发病率为8.4%(TF入路为4.4%,非TF入路为16.5%),出院时仅不到三分之一的患者接受抗凝治疗,术后AF与院内和1年死亡率、卒中风险升高相关。

Circ: Cardiovascular Interventions:动脉粥样硬化的程度可以预测TAVR后急性肾损伤的发生、严重程度和恢复

肾上腺动脉粥样硬化负荷与TAVR后AKI的发生、严重程度和恢复相关。

Circulation:经导管主动脉瓣置换术的排队时间与临床预后的相关趋势

经导管主动脉瓣置换术(TAVR)标志着重度主动脉瓣狭窄的治疗方案的模式转变。但是,TAVR需求的快速指数增长可能会导致等候时间延长,很多患者得不到医治。本研究的目的是评估TAVR排队时间与临床预后的相关时间趋势。本研究是在加拿大开展的以人口为基础的研究,研究人员收集2010年4月1日-2016年3月31日期间需要行TAVR的患者数据。主要指标是从确定到进行手术的总体中位排队时间。在2012年9月省

JACC:术后即刻12导联心电图可作为TAVR后晚期传导缺陷的预测因子

对于以下无右束支传导阻滞的患者TAVR后立即移除临时起搏器是安全的:1)窦性心律、伴PR间期<240ms且QRS间期<150ms;或2)房颤并且QRS间期<140ms。